Neurofibromatosis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials

Individual Patient Compassionate Use of Mirdametinib
Conditions:   Neurofibromatosis Type 1-Associated Plexiform Neurofibromas;   Histiocytic Neoplasm;   Other MAP-K Pathway Driven Diseases Intervention:   Drug: Mirdametinib (MEK Inhibitor) Sponsor:   SpringWorks Therapeutics, Inc. Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 31, 2021 Category: Research Source Type: clinical trials